论文部分内容阅读
目的:对比培美曲赛与多西他赛单药二线治疗局部晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的临床疗效。方法:将98例晚期NSCLC患者根据入院顺序按随机数字表法分为培美曲赛组与多西他赛组,每组各49例。培美曲赛组给予培美曲赛化疗,多西他赛组给予多西他赛化疗。对比两组近期疗效、生存质量及不良反应发生情况。结果:治疗后,两组总有效率、疾病控制率、躯体、角色认知功能及整体生活质量方面比较差异统计学意义(P>0.05)。培美曲赛组1年生存率为25.57%(14/49),多西他赛组1年生存率为18.36%(9/49),两组比较差异无统计学意义(P>0.05)。不良反应方面,培美曲赛组白细胞减少、恶心呕吐及脱发的发生率明显低于多西他赛组(P<0.05或P<0.01),放射性食管炎、放射性肺炎、血小板减少及皮疹的发生率两组差异无统计学意义(P>0.05)。结论:培美曲赛单药治疗局部晚期NSCLC的临床疗效与多西他赛相当,但毒副作用较小,安全性更高。
Objective: To compare the clinical efficacy of pemetrexed and docetaxel monotherapy in the treatment of locally advanced non-small cell lung cancer (NSCLC). Methods: Ninety-nine patients with advanced NSCLC were divided into Pemetrexed group and Docetaxel group according to the sequence of admission according to random number table. Pemetrexed group Pemeimeisu chemotherapy, docetaxel group given docetaxel chemotherapy. Compare the two groups of short-term efficacy, quality of life and adverse reactions. Results: After treatment, the total effective rate, disease control rate, body function, role cognitive function and overall quality of life were significantly different (P> 0.05). The one-year survival rate was 25.57% (14/49) in Pemetrexed group and 18.36% (9/49) in docetaxel group. There was no significant difference between the two groups (P> 0.05). Adverse reactions, pemetrexed group leukopenia, nausea and vomiting and hair loss was significantly lower than the docetaxel group (P <0.05 or P <0.01), radiation esophagitis, radiation pneumonitis, thrombocytopenia and the occurrence of rash Rate difference between the two groups was not statistically significant (P> 0.05). Conclusion: Pemetrexed monotherapy for the treatment of locally advanced NSCLC clinical efficacy comparable docetaxel, but less toxic side effects, higher safety.